Ginkgo Bioworks Holdings, Inc. (DNABW)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 200M 400M 600M Q2 '21: 133.1M Q3 '21: 197.4M Q4 '21: 313.8M Q1 '22: 438.1M Q2 '22: 539.1M Q3 '22: 527.9M Q4 '22: 477.7M Q1 '23: 390M Q2 '23: 326M Q3 '23: 315M Q4 '23: 251.5M Q1 '24: 208.7M Q2 '24: 184.3M Q3 '24: 218M Q4 '24: 227M Q1 '25: 227.3M Q2 '25: 210.3M Q3 '25: 160M Q4 '25: 149.6M Q1 '26: 130.8M Q2 '26: 111.9M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Gross Profit TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income TTM

-4.5B -3B -1.5B 0 1.5B 3B 4.5B Q2 '21: -207.4M Q3 '21: -199.6M Q4 '21: -1.8B Q1 '22: -2.4B Q2 '22: -3B Q3 '22: -3.7B Q4 '22: -2.2B Q1 '23: -1.7B Q2 '23: -1.3B Q3 '23: -917.2M Q4 '23: -864.4M Q1 '24: -826.7M Q2 '24: -865.5M Q3 '24: -634.3M Q4 '24: -559.8M Q1 '25: -462.7M Q2 '25: -297.9M Q3 '25: -332.8M Q4 '25: -299.9M Q1 '26: -290.3M Q2 '26: -290.7M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income TTM

-4.5B -3B -1.5B 0 1.5B 3B 4.5B Q4 '20: -127.2M Q1 '21: -175.3M Q2 '21: -200.5M Q3 '21: -276.3M Q4 '21: -1.8B Q1 '22: -2.3B Q2 '22: -3B Q3 '22: -3.5B Q4 '22: -2.1B Q1 '23: -1.7B Q2 '23: -1.2B Q3 '23: -856.6M Q4 '23: -892.9M Q1 '24: -853.8M Q2 '24: -897.7M Q3 '24: -651.2M Q4 '24: -547M Q1 '25: -472.1M Q2 '25: -315.2M Q3 '25: -339.5M Q4 '25: -312.8M Q1 '26: -304.4M Q2 '26: -290.8M Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow TTM

-450M -300M -150M 0 150M 300M 450M Q3 '21: -147.6M Q4 '21: -253.8M Q1 '22: -225.6M Q2 '22: -290.1M Q3 '22: -313.2M Q4 '22: -252.2M Q1 '23: -322.9M Q2 '23: -297M Q3 '23: -342.2M Q4 '23: -295.5M Q1 '24: -294.2M Q2 '24: -305M Q3 '24: -335M Q4 '24: -319.6M Q1 '25: -281.8M Q2 '25: -237.7M Q3 '25: -165.8M Q4 '25: -171.1M Q1 '26: -166.2M Q2 '26: -170.2M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow TTM

-450M -300M -150M 0 150M 300M 450M Q3 '21: -218.4M Q4 '21: -310.3M Q1 '22: -263.8M Q2 '22: -313.8M Q3 '22: -344.9M Q4 '22: -304.5M Q1 '23: -391M Q2 '23: -369.1M Q3 '23: -405.2M Q4 '23: -336.3M Q1 '24: -322.2M Q2 '24: -346.6M Q3 '24: -387.3M Q4 '24: -382.1M Q1 '25: -345.3M Q2 '25: -274.2M Q3 '25: -187.2M Q4 '25: -178.7M Q1 '26: -168.2M Q2 '26: -174.8M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 700M 1.4B 2.1B Q2 '21: 1.3B Q3 '21: 1.3B Q1 '22: 1.6M Q2 '22: 1.6B Q3 '22: 1.6B Q1 '23: 1.9B Q2 '23: 1.9B Q3 '23: 48.8M Q1 '24: 50.1M Q2 '24: 51.4M Q3 '24: 52.2M Q1 '25: 54.2M Q2 '25: 54.9M Q3 '25: 55.6M Q1 '26: 59.6M Q2 '26: 62.1M Q3 '21 Q2 '22 Q1 '23 Q3 '23 Q2 '24 Q1 '25 Q3 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-60.00 -40.00 -20.00 0.00 20.00 40.00 60.00 Q4 '21: -1.39 Q1 '23: -49.94 Q2 '23: -49.62 Q3 '23: -55.42 Q4 '23: -10.69 Q1 '24: -13.90 Q2 '24: -18.04 Q3 '24: -12.91 Q4 '24: -10.59 Q1 '25: -8.95 Q2 '25: -5.82 Q3 '25: -6.19 Q4 '25: -5.65 Q1 '26: -5.36 Q2 '26: -5.01 Q4 '21 Q2 '23 Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.